ARTICLE | Finance
Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market
June 2, 2020 2:00 AM UTC
Updated on Jun 2, 2020 at 8:54 PM UTC
Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital.
New investors Temasek, CR-CP Life Science Fund, Haitong Capital and Cavenham PE participated in the financing...